Bioscience Park Center
12635 E Montview Boulevard
54 articles with Ocugen, Inc.
Ocugen, Inc. announced the appointment of James G. Murphy, CPA, to the role of Chief Financial Officer.
Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease
Ocugen, Inc. announced that it has initiated the first of two pivotal, Phase 3 clinical trials of OCU300
Ocugen, Inc. announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held April 29 - May 3, 2018, in Honolulu, Hawaii.
Ocugen announced this morning that its mid-stage combination treatment hit its primary endpoint of tolerability in a proof-of-concept trial.
Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform
Ocugen has obtained an exclusive worldwide license to develop and commercialize future ophthalmology products based on groundbreaking technology from the Schepens Eye Research Institute of Massachusetts Eye and Ear.
Ocugen, Inc. Announces FDA Acceptance Of Investigational New Drug Application For OCU310 (Brimonidine/Steroid Combination Therapy) And Initiates Proof Of Concept Study For Treatment Of Dry Eye Disease
Ocugen, Inc. Receives FDA Orphan Drug Designation For OCU300 (Brimonidine Tartrate) For The Treatment Of Ocular Graft Versus Host Disease